U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07000630) titled 'Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis' on May 24.
Brief Summary: The goal of this clinical trial is to investigate the efficacy and safety of Deucravacitinib in patients with moderate-to-severe palmoplantar pustulosis. Approximately 25 subjects will be included in the study and receive Deucravacitinib 6mg per day for four months. This study will begin June 2025 and is expected to last 14 months.
Study Start Date: June 04
Study Type: INTERVENTIONAL
Condition:
Palmoplantar Pustulosis
Intervention:
DRUG: Deucravacitinib
25 subjects with palmoplantar pustulosis will be allocated ...